Previous 10 | Next 10 |
Piper Sandler analyst Steven Mah has upgraded gene-sequencing biotech Pacific Biosciences of California (PACB) to overweight from neutral.His new price target is $52, up from $20.Mah bases his upgrade on the recent $900M cash infusion from Softbank and improved long-term outlook.Pacific Biosc...
Pacific Biosciences of California (NASDAQ: PACB) no doubt made many investors happy in 2020, as its shares more than quintupled in value. The genetic sequencing systems stock is off to a great start in 2021 as well, with a year-to-date gain of 80%. The good times should keep rol...
Image source: The Motley Fool. Pacific Biosciences of California (NASDAQ: PACB) Q4 2020 Earnings Call Feb 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Pacific Biosciences of California (PACB) Q4 2020 Earnings...
Pacific Biosciences of California, Inc. (PACB) Q4, 2020 Earnings Conference Call February 10, 2021 04:30 PM ET Company Participants Trevin Rard - Investor Relations Christian Henry - President & Chief Executive Office Susan Kim - Chief Financial Officer Mark Van Oene - Chief Operating Off...
Shares of Pacific Biosciences of California (NASDAQ: PACB) surged 16% on Wednesday after the DNA sequencing leader said it obtained a strategic investment from Japanese technology conglomerate SoftBank Group (OTC: SFTB.Y) . Softbank subsidiary SB Management will purc...
Shares of Pacific Biosciences (NASDAQ: PACB) surged 16% on Wednesday after the DNA sequencing leader said it obtained a strategic investment from Japanese technology conglomerate SoftBank Group (OTC: SFTB.Y) . Softbank subsidiary SB Management will purchase $900 mill...
Pacific Biosciences of California (PACB): Q4 GAAP EPS of $0.37 beats by $0.06.Revenue of $27.14M (-2.8% Y/Y) beats by $1.6M.Cash, equivalents and investments, excluding short-term restricted cash and long-term restricted cash, at Dec. 31, 2020 totaled $318.8M.Shares -1.96%.Press Release For...
MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Reported revenue is consistent with the Company’s press release issued on Janua...
Healthcare lagged the broader market last year, but that can change this year. A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare. Best positioned are industry groups within healthcare that can achieve secular growth beyond the cyclical rise. Biot...
Shares of gene sequencing specialist Pacific Biosciences of California (NASDAQ: PACB) are trading higher on Wednesday following the company's announcement that it will receive an investment from Softbank Group (OTC: SFTBF) . As of 12:13 p.m. EST, Pacific Biosciences' stock i...
News, Short Squeeze, Breakout and More Instantly...
Pacific Biosciences of California Inc. Company Name:
PACB Stock Symbol:
NASDAQ Market:
Pacific Biosciences of California Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
MENLO PARK, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that Novogene is using its Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany, se...
A look at the top 10 most actives in the United States Yoshitsu Co. Ltd (TKLF) rose 103.4% to $0.623 on volume of 309,019,720 shares Maxeon Solar Technologies Ltd. (MAXN) rose 11.2% to $0.2524 on volume of 226,231,487 shares NVIDIA Corporation (NVDA) fell 1.6% to $126.36 on volume of 208,...